The difference between benign prostatic hyperplasia and prostate cancer.

Written by Zhou Zi Hua
Oncology
Updated on September 14, 2024
00:00
00:00

Prostatic hyperplasia and prostate cancer are sometimes very difficult to distinguish clinically, as both diseases occur in elderly men, can cause lower urinary tract symptoms, and lead to elevated PSA levels. However, prostatic hyperplasia generally has a longer medical history, whereas prostate cancer has a shorter history and progresses more quickly. During a digital rectal exam for prostatic hyperplasia, the gland appears enlarged and the surface is smooth. In contrast, during a prostate exam, the gland may show irregular enlargement, a rough surface, and the tumor feels firm. When these two are difficult to distinguish, considering a prostate biopsy may be advisable.

Other Voices

doctor image
home-news-image
Written by Liu Liang
Oncology
51sec home-news-image

Can prostate cancer be cured?

Early-stage prostate cancer patients can achieve a cure through radical surgery or radical radiotherapy and other treatment methods. Therefore, whether prostate cancer can be cured is related to the stage of the patient's condition. Early-stage prostate cancer patients can be cured through radical surgery or radical radiotherapy. If the cancer is diagnosed at a late stage, with extensive pelvic metastasis or multiple bone metastases, treatment for these late-stage prostate cancer patients primarily revolves around endocrine therapy. Most patients respond well to endocrine treatment; however, for these late-stage prostate cancer patients, the treatment aims to alleviate symptoms and extend survival. Through these treatments, a cure is not achievable.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
37sec home-news-image

What causes prostate cancer?

The current causes of prostate cancer are not completely understood, but a large amount of research indicates that genetic and environmental factors play a significant role. Dietary factors, such as the intake of a large amount of unsaturated fatty acids, vasectomy, smoking, obesity, and alcohol consumption, also increase the risk of developing prostate cancer. Overall, the occurrence and development of prostate cancer are related to various factors, including both internal causes in the patient and the influence of external factors.

doctor image
home-news-image
Written by Liu Liang
Oncology
34sec home-news-image

What causes prostate cancer?

The causes of prostate cancer are not yet very clear. Its occurrence may be related to gonorrhea of the prostate, or viral and chlamydial infections of the prostate, as well as the intensity of sexual activity and the influence of hormones, which may have some connection to the development of prostate cancer. Additionally, a high-fat diet and some occupational factors, such as excessive exposure to chromium, may also be related to the onset of prostate cancer.

doctor image
home-news-image
Written by Liu Liang
Oncology
43sec home-news-image

Typical symptoms of prostate cancer

Early-stage prostate patients often do not exhibit significant clinical symptoms. However, when the prostate cancer tumor invades the surrounding tissues and structures, it can cause corresponding clinical manifestations such as urinary tract irritation and urinary obstruction. Symptoms include difficulty urinating or frequent urination, painful urination, and even urinary incontinence, perineal pain, and sciatica. Bone metastasis is a common site of metastasis in prostate cancer patients, causing pain in the affected area and even pathological fractures.

doctor image
home-news-image
Written by Zhou Zi Hua
Oncology
57sec home-news-image

Commonly used drugs for endocrine treatment of prostate cancer

The purpose of endocrine therapy for prostate cancer is to reduce the concentration of androgens in the body, inhibit the synthesis of androgens originating from the adrenal glands, inhibit the conversion of testosterone to dihydrotestosterone, or block the binding of androgens to their receptors, thereby inhibiting or controlling the growth of prostate cancer cells. The medications include a luteinizing hormone-releasing hormone analogue, with representative drugs being leuprorelin, goserelin, and triptorelin. There is also an androgen-blocking drug, including steroidal drugs with representative drugs like cyproterone acetate, and non-steroidal drugs with representative drugs like bicalutamide and flutamide. Additionally, there are estrogens, with the most common being diethylstilbestrol.